Lung cancer with acquired T790M resistance: erlotinib switched to afatinib while AZD9291/TAGRISSO trial was considered

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: Acquired resistance detected; other resistance findings also mentioned

As of January 2016, he had reached 2 years of survival but had confirmed acquired resistance including T790M, worsening symptoms, and a treatment change from erlotinib to afatinib while a TAGRISSO/AZD9291 trial was being considered.

Lung cancer progression on Tarceva with urgent T790M resistance testing planned

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: resistance suspected; bronchoscopy planned to test for it

As of January 2016, CT showed clear progression while he was taking Tarceva/erlotinib, so urgent bronchoscopy was planned to look for T790M resistance and guide the next treatment option.

EGFR-mutated NSCLC on Tarceva with CT follow-up pending and future resistance options discussed

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation; T790M resistance discussed as a possible future resistance mechanism

As of December 2015, he was on Tarceva/erlotinib for EGFR-mutated NSCLC, had new cough/chest pain/fatigue, and was waiting for a control CT to clarify whether the tumor remained controlled.